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Abstract
Background: We tried to evaluate the clinical outcomes (mortality, postoperative bleeding
and perioperative myocardial infarction) of patients who underwent first elective coronary
artery bypass grafting and received aspirin during the preoperative period.
Methods: The study was a prospective, randomized and single-blinded clinical trial. Two
hundred patients were included and divided into two groups. One group received aspirin 80–
–160 mg, while in the other aspirin was stopped at least seven days before surgery. The
primary end-points of the study were in-hospital mortality and hemorrhage-related complica-
tions (postoperative blood loss in the intensive care unit, re-exploration for bleeding and red
blood cell and non-red blood cell requirements). The secondary end-point was perioperative
myocardial infarction.
Results: There were no differences in patient characteristics between the aspirin users and
non-aspirin users. We found a significant difference between postoperative blood loss (608 ±
± 359.7 ml vs. 483 ± 251.5 ml; p = 0.005) and red blood cell product requirements (1.32 ±
± 0.97 unit packed cell vs. 0.94 ± 1.02 unit packed cell; p = 0.008). There was no significant
difference between the two groups regarding platelet requirement and the rate of in-hospital
mortality and re-exploration for bleeding. Similarly, we found no significant difference in the
incidence of definite and probable perioperative myocardial infarction (p = 0.24 and p = 0.56
respectively) or in-hospital mortality between the two groups.
Conclusion: Preoperative aspirin administration increased postoperative bleeding and red
blood cell requirements with no effect on mortality, re-exploration rate and perioperative myo-
cardial infarction. We recommend withdrawal of aspirin seven days prior to surgery. (Cardiol J
2007; 14: 453–457)
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Introduction
Aspirin is an effective therapy in the management
of stable and unstable coronary artery disease [1].
Early initiation of aspirin after coronary artery by-
pass graft (CABG) surgery reduces the risk of graft
occlusion [2]. Aspirin has been implicated in plate-
let dysfunction and prolongation of bleeding time, but
its effect on postoperative bleeding, re-exploration
and blood-product requirement is controversial [3–
–12]. In this study we tried to determine the effect
of preoperative aspirin use on in-hospital mortality,
postoperative bleeding, blood transfusion require-
ments and perioperative myocardial infarction (MI).
Methods
We conducted a prospective study on 200 pa-
tients (67 aspirin users were male vs. 70 non-aspi-
rin users, p = 0.761; mean age was 56.9 ± 9.14
years in aspirin users vs. 56.9 ± 9.59 years in non-
-aspirin users, p = 0.83), who underwent CABG
surgery in our cardiovascular surgery department
between November 2005 and December 2006. We
received ethical approval for the study and the pa-
tients gave their informed written consent to par-
ticipation in the study. We included patients who
were undergoing elective CABG for the first time.
Our exclusion criteria were: 1) the need for con-
comitant valvular, aortic or aneurysmectomy sur-
gery; 2) concomitant antiplatelet drug consumption,
including clopidogrel, ticlopidin, glucocorticoides,
non-steroid anti-inflammatory drugs. We used the
left internal mammary artery as a graft. The total
number of grafts was below five and all the opera-
tions were performed by a single surgical team.
Patient characteristics are summarized in Table 1.
The patients were randomly assigned into one
of two groups. Group 1 received aspirin preopera-
tively while in Group 2 aspirin was stopped at least
seven days before CABG. All patients received
a single dose of aprotinin (2,000,000 kallikrein inhib-
itor units) once during surgery. Aspirin was started
post-operatively within 6 h of CABG in both groups.
The immediate postoperative care of these
patients was provided by the staff of the cardiac
surgery intensive care unit (ICU). Pericardial and
pleural chest tube output was monitored frequent-
ly within the first few days of surgery and recorded
in the patient’s ICU file. Extubated stable patients
were transferred to a cardiac surgery step-down
unit after at least the second postoperative day.
The dates of all transfusion information were
entered into the hospital central computer from the
respective laboratories and these data were made
available by the use of the patient hospital identifica-
tion numbers. The use of red blood products or non-
red blood products such as fresh frozen plasma (FFP)
and platelets was at the discretion of the surgical team.
ECGs were recorded preoperatively and on the
first to fifth days after CABG. New QS waves on
ECG were recorded in the patients’ files.
Cardiac enzyme marker (CK-MB) samples were
collected preoperatively and at least five times
during the first and second day after CABG. A CK-MB
of more than 30 IU/L was suspicious for myocar-
dial injury during CABG.
In all patients two-dimensional echocardiogra-
phy was performed on the second and fifth days af-
ter CABG for detection of new regional wall mo-
tion abnormality (RWMA) in patients with a new QS
on ECG or CK-MB of more than 30 IU/L. The pri-
mary study end-points were hospital mortality, re-
exploration, excessive pericardial and pleural tube
bleeding and an excessive requirement for red blood
cell and non-red blood cell products.
The study was also extended to examine the
effect of preoperative aspirin prescription on the
rate of perioperative MI.
Definitions
Definite perioperative MI was defined by a new
QS on ECG and a new RWMA on ECHO with or
without CK-MB > 30 IU/L, and the definition of
Table 1. Patient characteristics.
Variables Aspirin user (n = 100) Non-aspirin user (n = 100) p
Left ventricular ejection fraction 41.7 ± 11.6 42.6 ± 11.3 0.69
Cigarette smokers 36 (36%) 36 (36%) 1.00
Dyslipidemic patients 53 (53%) 44 (44%) 0.26
Hypertensive patients 40 (40%) 36 (36%) 0.66
Presence of left ventricular hypertrophy 11 (11%) 15 (15%) 0.53
Diabetic patients 34 (34%) 23 (23%) 0.12
P value < 0.05 is significant.
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probable perioperative MI was CK-MB > 30 IU/L with
a new QS on ECG or a new RWMA on ECHO [13].
Statistical analysis
Statistical analysis was performed using SPSS®
11.5 (SPSS Inc. Chicago, IL, USA) for data storage
and analysis. Continuous data were expressed as
mean value ± SD. Comparison of baseline categor-
ical data was performed by the c² test and continu-
ous data were compared by a standard t-test. In all
analyses with a 95% confidence interval (CI),
p < 0.05 was considered statistically significant.
Results
One hundred (50% of the total) individuals re-
ceived aspirin, whereas this was discontinued in the
other group for at least seven days before CABG.
There were no significant differences between the
two groups in terms of mean age or sex. The pa-
tients’ characteristics are summarized in Table 1.
The aspirin users had more post-operative
bleeding (608 ± 359.7 ml vs. 483 ± 251.5 ml; p =
0.005) and received more red blood cell products
(1.32 ± 0.97 unit packed cell vs. 0.94 ± 1.02 unit
packed cell; p = 0.008) and FFP (2 ± 1.84 vs. 1.46
± 1.64; p = 0.03) early after surgery, although
platelet transfusion was not significantly different
between the two groups (0.45 ± 1.32 vs. 0.28 ± 0.84
unit platelet, p = 0.25). No in-hospital mortality was
observed in either group.
With regard to the secondary end-points of the
study, the aspirin users had a significantly lower
incidence of new QS patterns on ECG after CABG
(1% vs. 10%; p = 0.013), but CK-MB and RWMA
did not differ significantly between the two groups
(Table 2).
There was no significant difference in the inci-
dence of definite or probable perioperative MI.
Definite MI occurred in 0% of aspirin users vs. 3%
of non-aspirin users (p = 0.24) and probable MI oc-
curred in 5% in Group 1 vs. 8% in Group 2 (p = 0.56).
Discussion
This study indicated that the use of aspirin
before CABG is associated with a higher risk of
postoperative bleeding and an increased require-
ment for red blood cell products and FFP transfu-
sion. This finding was counter to other studies,
which showed that patients receiving aspirin were
no more likely to receive blood products [7–12].
Tuman et al. [8] showed that preoperative aspirin
consumption does not increase allogeneic blood
transfusion in reoperative coronary artery surgery.
In another study, Vuylsteke et al. [9] evaluated the
effect of aspirin in coronary artery bypass grafting
and showed that aspirin therapy did not appear to
increase blood loss, reopening for bleeding or blood
product usage requirements during the hospital
stay. On the other hand, there are studies that con-
firm our finding [3–6]. Ferraris et al. [6] evaluated
aspirin and postoperative bleeding after CABG.
Their findings support the hypothesis that aspirin
is associated with a greater likelihood of postoper-
ative bleeding. Recently Ferraris et al. wrote in clin-
ical practice guidelines that it was reasonable to
discontinue low intensity antiplatelet drugs such as
aspirin only in purely elective patients without
acute coronary syndromes before surgery in the
expectation that blood transfusion will be reduced
(Class II A, level of evidence A) [7].
In our study the re-exploration rate for bleed-
ing was 3% in each group without significant dif-
ferences (p = NS). Dacey et al. [11] found no sig-
nificant difference in the rate of re-exploration for
hemorrhage between patients who had and those
who had not received aspirin. Other studies
Table 2. Evaluation of perioperative myocardial infarction markers.
Variables Aspirin user (n = 100) Non-aspirin user (n = 100) p
New QS pattern
Yes 1 (1%) 10 (10%) 0.013
No 99 (99%) 90 (90%) 0.013
Rising CK-MB marker
Yes 11 (11%) 18 (18%) 0.23
No 89 (89%) 82 (82%) 0.23
New RWMA
Yes 5 (5%) 8 (8%) 0.57
No 95 (95%) 92 (92%) 0.57
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confirmed that pre-surgery aspirin prescription has
no effect on the re-exploration rate due to increased
bleeding [9], although Bashein et al. [5] concluded
that aspirin exposure within seven days of coronary
bypass surgery is associated with an increased rate
of reoperation for bleeding and that reoperation is
associated with large increases in transfusion re-
quirements and ICU and hospital stays. In the most
recent study Bybee et al. [15] showed that aspirin
usage within the five days preceding CABG is as-
sociated with a lower risk of post-operative in-hos-
pital mortality, appears to be safe and is not associ-
ated with any increased risk of reoperation for
bleeding or the need for blood product transfusion.
A reduction in the rate of perioperative MI has
been reported in aspirin users undergoing CABG.
Klein et al. [12] showed a reduction in the rate of
perioperative MI in patients receiving preoperative
aspirin. We evaluated the occurrence of definite
perioperative MI and probable perioperative MI in
two groups. New QS waves on ECG were signifi-
cantly lower in aspirin users (p = 0.013), but no
significant difference was found for an increase in
CK-MB or the appearance of new RWMA (Table 2).
The risk of definite or probable perioperative MI
was reduced with aspirin use before CABG but did
not achieve statistical significance.
Study limitations
This study was designed for evaluation of the
effect of aspirin on postoperative bleeding and in-
volved a small number of patients. In larger groups
we might therefore achieve statistical significance
in the rate of reduction of perioperative MI.
Conclusions
We found that aspirin use in patients undergo-
ing elective coronary artery bypass graft surgery
is associated with a marked elevation in postopera-
tive bleeding and the need for red blood cell and
fresh frozen plasma transfusion. We also found no
significant reduction in the rate of definite or prob-
able perioperative MI. We therefore prefer to dis-
continue aspirin consumption for at least seven days
before elective CABG.
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